
Core Insights - Enlivex Therapeutics Ltd. has been selected to present at the Israeli BioMed 2025 Conference, focusing on its macrophage reprogramming therapy, Allocetra™, for treating inflammatory diseases [1][2] Company Overview - Enlivex is a clinical-stage company specializing in macrophage reprogramming immunotherapy, developing Allocetra™, a universal, off-the-shelf cell therapy aimed at resetting macrophages to their homeostatic state [4] Product Details - Allocetra™ is designed to address non-homeostatic macrophages, which are linked to various chronic and life-threatening diseases, by reprogramming them to restore immune balance [2][4] - The company is advancing a clinical pipeline that includes multiple Phase I/II trials for conditions such as osteoarthritis and psoriatic arthritis [3] Clinical Trial Results - Recent interim data from a six-month study in moderate knee osteoarthritis indicated a 47% reduction in pain, a 46% improvement in joint function, and a 40% decrease in stiffness [3]